Paloma Partners’s Maravai LifeSciences MRVI Stock Holding History

Paloma Partners’s Portfolio MRVI Stock Details MRVI Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q4	–	Sell	-16,713	Closed	-$820K	–	2026
2021 Q3	$820K	Sell	16,713 -3,376	-17%	-$165K	0.02%	400
2021 Q2	$839K	Buy	20,089 +9,646	+92%	+$374K	0.02%	730
2021 Q1	$372K	Buy	+10,443	New	+$346K	0.01%	1343

Other funds holding MRVI

GTCR LLC Chicago, Illinois $3.78B AUM 27.82% 1-Year Est. Return

Select Equity Group New York $19.5B AUM 17.33% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Massachusetts Financial Services Boston, Massachusetts $298B AUM 21.96% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

UBS AM Chicago, Illinois $481B AUM 26.39% 1-Year Est. Return

CIP

Champlain Investment Partners Burlington, Vermont $7.88B AUM 6.82% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

OCBV

Ownership Capital B.V. Amsterdam, Netherlands $178M AUM 4.75% 1-Year Est. Return

Paloma Partners's MRVI Position: Q4 2021 in Review

Paloma Partners sold out of Maravai LifeSciences (MRVI) in Q4 2021, closing a stake of 16,713 shares — an estimated $820K sold.

Paloma Partners first reported a position in MRVI in Q1 2021 and held it in 3 quarters. The position peaked at $839K in Q2 2021. 229 funds tracked by Wall St. Rank hold MRVI as of Q4 2021.

Paloma Partners reported no remaining Maravai LifeSciences position as of Q4 2021 after selling out during the quarter.
Paloma Partners sold 16,713 Maravai LifeSciences shares in Q4 2021, an estimated $820K.
Paloma Partners first reported a position in Maravai LifeSciences in Q1 2021 and held it in 3 quarters.
Paloma Partners's Maravai LifeSciences position peaked at $839K in Q2 2021.
229 funds tracked by Wall St. Rank held Maravai LifeSciences as of Q4 2021.

Based on Paloma Partners's 13F filing for Q4 2021, filed 14 Feb 2022.